Collegium Pharmaceutical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Collegium Pharmaceutical reported record third-quarter 2026 net product revenues of $216.3 million, up 3% year-over-year.
- JORNAY PM revenue was $51.9 million, up 24% year-over-year, with prescriptions up 16% and nearly 33,000 healthcare providers writing prescriptions, up 19%.
- AZSTARYS generated $26.5 million in net revenue in its first full quarter under Collegium ownership; prescriptions grew nearly 2% year-over-year following a decline in 2025.
- Pain portfolio revenue was $138 million; BELBUCA revenue was $57.7 million, down 1% year-over-year, XTAMPZA ER revenue was $45.8 million, down 9%, and NUCYNTA franchise revenue was $30.8 million, down 44%.
- GAAP operating expenses were $96.7 million, up 44% year-over-year, and adjusted operating expenses were $69.4 million, up 25%. GAAP net income was $21.8 million, compared with $31.5 million in Q3 2025.
- Non-GAAP adjusted EBITDA was $121.6 million, down 9% year-over-year. GAAP EPS was $0.69 basic and $0.60 diluted, and non-GAAP adjusted EPS was $1.96.
- Operating cash flow was $86.5 million. As of September 30, 2026, Collegium had $144.8 million in cash equivalents and marketable securities, and net debt to adjusted EBITDA of approximately 2x.
- Collegium began a $50 million accelerated share repurchase program in Q3, expects to complete it before the end of the year, and has $100 million remaining on its share repurchase program authorized last July.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during this conference call, please press star 0 on your telephone keypad. Please note that this conference call is being recorded. I will now turn the call over to Ian Karp, Head of Investor Relations. Thank you. You may begin.
Great. Thanks, Maria, and welcome to Collegium Pharmaceutical's Third Quarter 2026 Earnings Conference Call. I am joined today by Vikram Karnani, our President and Chief Executive Officer, and Colleen Tupper, our Chief Financial Officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, as detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website.
With that, I'll now turn the call over to our President and CEO, Vikram Karnani.
Thank you, Ian. Good morning, everyone, and thank you for joining our Third Quarter 2026 Earnings Call. Collegium is a dynamic commercial-stage biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. Our success is built upon our proven ability to acquire, integrate, and grow differentiated medicines while creating long-term shareholder value. This strategy has established a portfolio of six differentiated medicines, reflecting the significant evolution our company has undertaken over the past several years. ADHD has become our lead growth driver, accounting for more than 36% of total revenue, up from just 19% last year. With JORNAY PM and AZSTARYS, we have two complementary medicines supported by an expanding commercial platform to drive future growth. Meanwhile, our pain portfolio continues to generate robust cash flows, providing the financial flexibility to invest in our ADHD portfolio and further diversify our business.
The team at Collegium remains focused, invigorated, and committed to making a meaningful difference in the lives of patients and creating long-term value for our shareholders. We delivered a record quarterly net revenue of $216.3 million, up 3% year-over-year, driven by growth in ADHD during the important back-to-school season. Key achievements this quarter included: JORNAY PM prescriptions grew by 16%, generating a record $51.9 million in net revenue, up 24% year-over-year. JORNAY PM prescribers also reached another all-time high, with nearly 33,000 healthcare providers writing JORNAY PM prescriptions in the quarter, up 19% over Q3 of last year. Our investments in JORNAY PM are translating into broader prescriber adoption and continued prescription growth. AZSTARYS generated $26.5 million in net revenue during its first full quarter under our ownership. Prescriptions grew nearly 2% year-over-year, following a decline in 2025.
This is an early indication of the opportunity to grow AZSTARYS through our expanded ADHD commercial platform. Our pain portfolio generated $138 million in revenue during the quarter, continuing to make a meaningful contribution to our business. Performance was in line with our expectations and consistent with our 2026 full-year financial guidance. Turning now to other recent corporate updates. We are continuously seeking ways to support the ADHD patient community, and in October, which was ADHD Awareness Month, we announced two new initiatives. First, we launched Start Talking ADHD, our online resource hub offering practical guides to people living with ADHD and their caregivers.
Next, we established a new multi-year partnership with Boston Legacy FC, Boston's professional women's soccer club, focused on promoting inclusion and accessibility through youth coach training, an annual Sports for All Summit, and sensory inclusion programs designed to support neurodivergent children and their families, including those living with ADHD. We also further advanced our capital allocation strategy by returning capital to shareholders through a $50 million accelerated share repurchase program announced in the third quarter. We expect to complete the full repurchase amount before the end of the year and have $100 million remaining on our share repurchase program that was authorized by our board last July. As we look toward the end of 2026 and move into next year, we remain focused on three key strategic priorities: growing our ADHD business, maximizing the value of our pain portfolio, and strategically deploying capital to create long-term shareholder value.
Our ADHD portfolio performed particularly well in the third quarter, further supported by our promotional activities, expanded sales force, and the back-to-school season. The momentum across our ADHD business has enabled us to reaffirm our full-year 2026 guidance, which includes $190 million-$200 million in JORNAY PM revenues, a 31% increase year-over-year at the midpoint, and $65 million-$75 million in partial-year AZSTARYS revenues. In pain, our focus is on maximizing portfolio value and cash generation. That cash flow supports investment in ADHD and provides flexibility to pursue business development, repay debt, and return capital to shareholders. Turning to our leadership position in ADHD, we now have a unified commercial organization focused on accelerating growth and maximizing operational leverage.
At the foundation of this franchise are JORNAY PM and AZSTARYS, two differentiated and complementary medicines that serve different patient types, allowing us to address the unmet needs of a wide range of patients. Both medicines can last all day and offer a smooth offset, helping to avoid a treatment crash, which can be seen with other ADHD medicines. The main differences between JORNAY and AZSTARYS are in the timing of their symptom control. JORNAY PM is the first and only stimulant dosed at night, delivering symptom control without delay upon awakening. JORNAY PM is often preferred by the patient whose symptoms are particularly challenging first thing in the morning and who needs their all-day symptom control to start immediately upon awakening. AZSTARYS is the first and only ADHD stimulant treatment with both fast and long-acting medicines in one capsule, delivering rapid all-day symptom control.
AZSTARYS is often preferred by the patient who has more variability in their daily schedule and needs the flexibility of rapid onset symptom control and efficacy to last later into the evening. In fact, driven by our targeted investments and enhanced commercial efforts, HCP perceptions of JORNAY PM are increasingly positive. Based on market research completed earlier this year, HCPs had a high favorability rating and ranked JORNAY PM as the number 1 branded ADHD medicine in terms of product differentiation, with a score significantly higher than all other medicines in the same category. The same market research conducted prior to Collegium's acquisition of AZSTARYS also yielded important insights into AZSTARYS' market opportunity. Namely, it was viewed as meaningfully differentiated in the ADHD treatment landscape, and more than half of physicians surveyed indicated an intent to increase prescribing in the future.
We believe there is a significant opportunity to increase HCP perception of AZSTARYS in the months and quarters ahead by utilizing our enhanced ADHD commercial platform. Encouragingly, Collegium ranked number 1 in reputation among pharmaceutical companies specializing in ADHD. Combined, JORNAY PM and AZSTARYS now command approximately 55% share of the total branded long-acting methylphenidate market. With the majority of the long-acting methylphenidate market comprised of generics, we believe there remains a significant opportunity to capture additional share, particularly among patients who are dissatisfied with their current generic treatment. This quarter, JORNAY PM remained the fastest-growing stimulant for the treatment of ADHD and demonstrated strong performance across a number of key metrics. Prescriptions grew 16% year-over-year. Prescribers hit an all-time high with nearly 33,000 healthcare providers writing JORNAY PM prescriptions, up 19% year-over-year.
JORNAY PM's share in the branded long-acting methylphenidate market also hit an all-time high at approximately 30%, up 6.5 percentage points year-over-year. We also saw solid growth across both the pediatric and adult segments. In the pediatric and adolescent segment, which represents about 80% of our business, total prescriptions grew 13% year-over-year. Growth was even stronger in the adult segment, representing about 20% of our overall prescriptions, which grew 27% year-over-year. New-to-brand prescriptions provided another measure of potentially accelerating demand, capturing patients who were new to JORNAY or have not received a prescription in the prior 12 months. In September, the first full month of the back-to-school season, new-to-brand prescriptions grew 22% year-over-year, and that momentum has accelerated in October.
Bolstered by the back-to-school season, JORNAY PM delivered particularly strong performance this quarter, and our priority is to sustain prescription growth throughout the remainder of the year. This was also our first full quarter promoting AZSTARYS, and we are just beginning to see the benefits of having two differentiated and complementary ADHD medicines in our portfolio. In addition, prior to our acquisition of AZSTARYS, commercial investment in the product was limited and at times inconsistent. This likely contributed to AZSTARYS' total prescriptions declining by nearly 2% in 2025. Despite these declining volumes, market research suggested that AZSTARYS was the second most differentiated stimulant brand following JORNAY PM. With its strong brand fundamentals, coupled with our commercial expertise and track record of growing acquired products, we believe that we can maximize AZSTARYS' growth potential in the years ahead.
We have already started to see early signs of success, with prescriptions up nearly 2% year-over-year in the third quarter, following an annual prescription decline in 2025. Importantly, AZSTARYS has IP protection through 2037, extending the life cycle of our commercial portfolio and giving us additional time to maximize the reach and full value of AZSTARYS. Following the close of the AZSTARYS acquisition in May, we were able to rapidly and seamlessly integrate AZSTARYS into our commercial infrastructure. We have made targeted investments, expanding our ADHD commercial team and marketing capabilities. We grew our ADHD sales force to about 190 reps, up from 180 prior to the acquisition, and our target HCPs to about 27,000, up from 21,000 pre-expansion in 2025. We also recently expanded our medical affairs team to better support both products from a clinical standpoint.
All of our sales representatives were fully trained and selling both products to their targeted HCPs in July, ahead of the back-to-school season to maximize impact. We are now deploying our target HCP, patient, and caregiver marketing efforts for both JORNAY PM and AZSTARYS. Early initiatives include focused AI-targeted digital marketing campaigns, peer-to-peer programming, and increasingly shifting investment towards awareness-driving brand campaigns built on each product's clinical strengths. Turning to our responsible pain management business. This portfolio, comprised of BELBUCA, XTAMPZA, and NUCYNTA, continues to provide a solid foundation for Collegium that, through its strong cash generation, provides financial flexibility to invest in the growth of our ADHD business, execute disciplined business development opportunities, and return capital to shareholders. BELBUCA delivered solid performance again this quarter, with revenues of $57.7 million, broadly flat year-over-year and sequentially.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
